Frederick S Buckner

List of Publications by Year in Descending Order

134 papers	5,320 citations	42 h-index	67 g-index
140 ext. papers	5,843 ext. citations	6.2 avg, IF	5.04 L-index

#	Paper	IF	Citations
134	Early Stages of Drug Discovery in an Academic Institution and Involvement of Pharma for Advancing Promising Leads. *ACS Infectious Diseases*, **2021**, 7, 1874-1876	5.5	0
133	Spontaneous Selection of Drug Resistance in a Calf Model of Infection. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	4
132	Case Report: Miltefosine Failure and Spontaneous Resolution of Cutaneous Leishmaniasis braziliensis. *American Journal of Tropical Medicine and Hygiene*, **2021**,	3.2	1
131	Synthesis and Structure-Activity Relationships of Imidazopyridine/Pyrimidine- and Furopyridine-Based Anti-infective Agents against Trypanosomiases. *ChemMedChem*, **2021**, 16, 966-975	3.7	10
130	The Tryp and the Pendulum. *EBioMedicine*, **2021**, 64, 103188	8.8	
129	Structure-guided discovery of selective methionyl-tRNA synthetase inhibitors with potent activity against. *RSC Medicinal Chemistry*, **2020**, 11, 885-895	3.5	5
128	Methionyl-tRNA synthetase inhibitor has potent in vivo activity in a novel Giardia lamblia luciferase murine infection model. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1218-1227	5.1	5
127	Phenotypic Drug Discovery for Human African Trypanosomiasis: A Powerful Approach. *Tropical Medicine and Infectious Disease*, **2020**, 5,	3.5	3
126	A 71-year-old man with recurrent pulmonary mycobacterial avium complex infections and lymphopenia. *Allergy and Asthma Proceedings*, **2020**, 41, 66-69	2.6	1
125	Clinical Features and Outcomes of 105 Hospitalized Patients With COVID-19 in Seattle, Washington. *Clinical Infectious Diseases*, **2020**, 71, 2167-2173	11.6	77
124	A new chemotype with promise against Trypanosoma cruzi. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 126778	2.9	
123	Setting Our Sights on Infectious Diseases. *ACS Infectious Diseases*, **2020**, 6, 3-13	5.5	9
122	Discovery of Drugs for Leishmaniases: A Progress Report. *Methods and Principles in Medicinal Chemistry*, **2019**, 139-160	0.4	1
121	Bioactivity of Farnesyltransferase Inhibitors Against and. *Frontiers in Cellular and Infection Microbiology*, **2019**, 9, 180	5.9	6
120	Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of Infection. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	21
119	Triazolopyrimidines and Imidazopyridines: Structure-Activity Relationships and in Vivo Efficacy for Trypanosomiasis. *ACS Medicinal Chemistry Letters*, **2019**, 10, 105-110	4.3	13
118	The crystal structure of the drug target Mycobacterium tuberculosis methionyl-tRNA synthetase in complex with a catalytic intermediate. *Acta Crystallographica Section F, Structural Biology Communications*, **2018**, 74, 245-254	1.1	7

117	From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis. *ACS Infectious Diseases*, **2017**, 3, 225-236	5.5	14
116	Leishmania donovani tyrosyl-tRNA synthetase structure in complex with a tyrosyl adenylate analog and comparisons with human and protozoan counterparts. *Biochimie*, **2017**, 138, 124-136	4.6	8
115	Optimization of a binding fragment targeting the "enlarged methionine pocket" leads to potent Trypanosoma brucei methionyl-tRNA synthetase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 2702-2707	2.9	9
114	Urea Derivatives of 2-Aryl-benzothiazol-5-amines: A New Class of Potential Drugs for Human African Trypanosomiasis. *Journal of Medicinal Chemistry*, **2017**, 60, 957-971	8.3	33
113	Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	17
112	1-Benzyl-3-aryl-2-thiohydantoin Derivatives as New Anti- Agents: SAR and in Vivo Efficacy. *ACS Medicinal Chemistry Letters*, **2017**, 8, 886-891	4.3	16
111	New Class of Antitrypanosomal Agents Based on Imidazopyridines. *ACS Medicinal Chemistry Letters*, **2017**, 8, 766-770	4.3	15
110	Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 1571-1584	3.4	8
109	Structure-guided design of novel Trypanosoma brucei Methionyl-tRNA synthetase inhibitors. *European Journal of Medicinal Chemistry*, **2016**, 124, 1081-1092	6.8	15
108	5-Fluoroimidazo[4,5-b]pyridine Is a Privileged Fragment That Conveys Bioavailability to Potent Trypanosomal Methionyl-tRNA Synthetase Inhibitors. *ACS Infectious Diseases*, **2016**, 2, 399-404	5.5	21
107	Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis. *PLoS ONE*, **2016**, 11, e0160350	3.7	13
106	Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. *Nature* , **2016**, 537, 229-233	50.4	249
105	A binding hotspot in Trypanosoma cruzi histidyl-tRNA synthetase revealed by fragment-based crystallographic cocktail screens. *Acta Crystallographica Section D: Biological Crystallography*, **2015**, 71, 1684-98		15
104	Inhibitors of methionyl-tRNA synthetase have potent activity against Giardia intestinalis trophozoites. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 7128-31	5.9	15
103	Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening. *Journal of Biomolecular Screening*, **2015**, 20, 122-30		25
102	Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. *Journal of Medicinal Chemistry*, **2014**, 57, 828-35	8.3	57
101	Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. *Chemical Reviews*, **2014**, 114, 11305-47	68.1	217
100	Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2775	4.8	29

99	Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2977	4.8	66
98	Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14□demethylase as anti-Chagas disease agents. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6492-9	2.9	11
97	Crystal structures of Plasmodium falciparum cytosolic tryptophanyl-tRNA synthetase and its potential as a target for structure-guided drug design. *Molecular and Biochemical Parasitology*, **2013**, 189, 26-32	1.9	21
96	Induced resistance to methionyl-tRNA synthetase inhibitors in Trypanosoma brucei is due to overexpression of the target. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 3021-8	5.9	14
95	Structure of the prolyl-tRNA synthetase from the eukaryotic pathogen Giardia lamblia. *Acta Crystallographica Section D: Biological Crystallography*, **2012**, 68, 1194-200		8
94	Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. *International Journal for Parasitology: Drugs and Drug Resistance*, **2012**, 2, 236-242	4	73
93	Recent highlights in anti-protozoan drug development and resistance research. *International Journal for Parasitology: Drugs and Drug Resistance*, **2012**, 2, 230-5	4	17
92	Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. *Journal of Medicinal Chemistry*, **2012**, 55, 6342-51	8.3	51
91	Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against Plasmodium falciparum dihydroorotate dehydrogenase. *Journal of Medicinal Chemistry*, **2012**, 55, 7425-36	8.3	49
90	Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. *Structure*, **2012**, 20, 1681-91	5.2	54
89	Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4914-21	5.9	46
88	Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection. *Advances in Parasitology*, **2011**, 75, 89-119	3.2	23
87	Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. *Biochimie*, **2011**, 93, 570-82	4.6	36
86	Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. *Journal of Medicinal Chemistry*, **2011**, 54, 3935-49	8.3	130
85	The double-length tyrosyl-tRNA synthetase from the eukaryote Leishmania major forms an intrinsically asymmetric pseudo-dimer. *Journal of Molecular Biology*, **2011**, 409, 159-76	6.5	30
84	Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase. *Molecular and Biochemical Parasitology*, **2011**, 177, 20-8	1.9	13
83	Screening a fragment cocktail library using ultrafiltration. *Analytical and Bioanalytical Chemistry*, **2011**, 401, 1585-91	4.4	9
82	Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 1982-9	5.9	65

81	An essential farnesylated kinesin in Trypanosoma brucei. *PLoS ONE*, **2011**, 6, e26508	3.7	3
80	Advances in Chagas disease drug development: 2009-2010. *Current Opinion in Infectious Diseases*, **2010**, 23, 609-16	5.4	49
79	Prediction of protein crystallization outcome using a hybrid method. *Journal of Structural Biology*, **2010**, 171, 64-73	3.4	12
78	The structure of tryptophanyl-tRNA synthetase from Giardia lamblia reveals divergence from eukaryotic homologs. *Journal of Structural Biology*, **2010**, 171, 238-43	3.4	10
77	The crystal structure and activity of a putative trypanosomal nucleoside phosphorylase reveal it to be a homodimeric uridine phosphorylase. *Journal of Molecular Biology*, **2010**, 396, 1244-59	6.5	14
76	Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. *Journal of Molecular Biology*, **2010**, 397, 481-94	6.5	32
75	Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. *Nature Structural and Molecular Biology*, **2010**, 17, 602-7	17.6	144
74	Delusional parasitosis: six-year experience with 23 consecutive cases at an academic medical center. *International Journal of Infectious Diseases*, **2010**, 14, e317-21	10.5	24
73	Crystal structure of the aspartyl-tRNA synthetase from Entamoeba histolytica. *Molecular and Biochemical Parasitology*, **2010**, 169, 95-100	1.9	13
72	Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. *Journal of Medicinal Chemistry*, **2010**, 53, 3887-98	8.3	91
71	Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands. *Journal of Biomolecular Screening*, **2009**, 14, 700-7		41
70	Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium. *Current Topics in Medicinal Chemistry*, **2009**, 9, 1678-87	3	33
69	Heterologous expression of L. major proteins in S. cerevisiae: a test of solubility, purity, and gene recoding. *Journal of Structural and Functional Genomics*, **2009**, 10, 233-47		40
68	Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6582-4	2.9	16
67	Rational modification of a candidate cancer drug for use against Chagas disease. *Journal of Medicinal Chemistry*, **2009**, 52, 1639-47	8.3	130
66	Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. *Journal of Medicinal Chemistry*, **2009**, 52, 3703-15	8.3	33
65	Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. *Journal of Medicinal Chemistry*, **2009**, 52, 1864-72	8.3	191
64	Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone. *Journal of Antimicrobial Chemotherapy*, **2009**, 63, 469-72	5.1	30

63	Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. *PLoS Neglected Tropical Diseases*, **2009**, 3, e384	4.8	56
62	High-throughput screening of amastigotes of Leishmania donovani clinical isolates against drugs using a colorimetric beta-lactamase assay. *Indian Journal of Experimental Biology*, **2009**, 47, 475-9		18
61	Genomic-scale prioritization of drug targets: the TDR Targets database. *Nature Reviews Drug Discovery*, **2008**, 7, 900-7	64.1	244
60	Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. *Molecular Microbiology*, **2008**, 68, 37-50	4.1	65
59	Protein geranylgeranyltransferase-I of Trypanosoma cruzi. *Molecular and Biochemical Parasitology*, **2008**, 157, 32-43	1.9	14
58	Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. *Advances in Experimental Medicine and Biology*, **2008**, 625, 61-80	3.6	37
57	Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. *Journal of Medicinal Chemistry*, **2008**, 51, 5176-97	8.3	32
56	Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity. *Journal of Molecular Biology*, **2008**, 381, 975-88	6.5	28
55	Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 3710-7	5.9	71
54	Structure of a Trypanosoma brucei alpha/beta-hydrolase fold protein with unknown function. *Acta Crystallographica Section F: Structural Biology Communications*, **2008**, 64, 474-8		4
53	Structural genomics of pathogenic protozoa: an overview. *Methods in Molecular Biology*, **2008**, 426, 497-513	1.4	34
52	Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. *Journal of Medicinal Chemistry*, **2007**, 50, 4585-605	8.3	57
51	The structure of Plasmodium vivax phosphatidylethanolamine-binding protein suggests a functional motif containing a left-handed helix. *Acta Crystallographica Section F: Structural Biology Communications*, **2007**, 63, 178-82		5
50	C-terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. *Molecular and Biochemical Parasitology*, **2007**, 153, 115-24	1.9	19
49	Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3659-71	5.9	33
48	Confirmation of Chagas cardiomyopathy following heart transplantation. *Heart and Vessels*, **2006**, 21, 325-7	2.1	4
47	Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. *Molecular and Biochemical Parasitology*, **2006**, 148, 144-60	1.9	155
46	Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. *Journal of Medicinal Chemistry*, **2006**, 49, 5710-27	8.3	32

45	Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. *Journal of Lipid Research*, **2006**, 47, 233-40	6.3	88
44	Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. *Journal of Medicinal Chemistry*, **2006**, 49, 5939-46	8.3	59
43	Structure of the conserved hypothetical protein MAL13P1.257 from Plasmodium falciparum. *Acta Crystallographica Section F: Structural Biology Communications*, **2006**, 62, 180-5		8
42	Structure of ribose 5-phosphate isomerase from Plasmodium falciparum. *Acta Crystallographica Section F: Structural Biology Communications*, **2006**, 62, 427-31		11
41	Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 A resolution reveals intriguing extra electron density in the active site. *Proteins: Structure, Function and Bioinformatics*, **2006**, 62, 570-7	4.2	27
40	The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. *Journal of Medicinal Chemistry*, **2005**, 48, 5415-8	8.3	74
39	Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. *Journal of Medicinal Chemistry*, **2005**, 48, 3704-13	8.3	153
38	Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation. *Transfusion*, **2005**, 45, 1459-63	2.9	46
37	Differential drug binding by the highly conserved Plasmodium falciparum thymidylate synthase. *Molecular and Biochemical Parasitology*, **2005**, 143, 121-4	1.9	7
36	Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. *Molecular and Biochemical Parasitology*, **2005**, 144, 68-75	1.9	18
35	Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. *Angewandte Chemie - International Edition*, **2005**, 44, 4903-6	16.4	34
34	Structurally Simple Farnesyltransferase Inhibitors Arrest the Growth of Malaria Parasites. *Angewandte Chemie*, **2005**, 117, 4981-4984	3.6	1
33	COLORIMETRIC ASSAY FOR SCREENING COMPOUNDS AGAINST LEISHMANIA AMASTIGOTES GROWN IN MACROPHAGES. *American Journal of Tropical Medicine and Hygiene*, **2005**, 72, 600-605	3.2	39
32	Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. *American Journal of Tropical Medicine and Hygiene*, **2005**, 72, 600-5	3.2	25
31	Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. *Current Opinion in Investigational Drugs*, **2005**, 6, 791-7		28
30	In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 6517-26	3.4	36
29	Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. *Journal of Medicinal Chemistry*, **2004**, 47, 432-45	8.3	46
28	A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 15149-53	11.5	61

27	Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. *Molecular and Biochemical Parasitology*, **2003**, 132, 75-81	1.9	18
26	Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. *Molecular and Biochemical Parasitology*, **2003**, 126, 155-63	1.9	120
25	Oxidosqualene cyclase inhibitors as antimicrobial agents. *Journal of Medicinal Chemistry*, **2003**, 46, 4240-8	8.3	33
24	Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major. *Molecular and Biochemical Parasitology*, **2002**, 122, 181-8	1.9	44
23	Isothiazole dioxides: synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 2217-20	2.9	25
22	Leishmania major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway. *Microbes and Infection*, **2002**, 4, 763-71	9.3	63
21	Trypanosoma brucei prenylated-protein carboxyl methyltransferase prefers farnesylated substrates. *Biochemical Journal*, **2002**, 367, 809-16	3.8	8
20	Cloning and functional characterization of a Trypanosoma brucei lanosterol 14alpha-demethylase gene. *Molecular and Biochemical Parasitology*, **2001**, 117, 115-7	1.9	6
19	TcRho1, a farnesylated Rho family homologue from Trypanosoma cruzi: cloning, trans-splicing, and prenylation studies. *Journal of Biological Chemistry*, **2001**, 276, 29711-8	5.4	31
18	Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 1210-5	5.9	68
17	Trypanosome and animal lanosterol synthases use different catalytic motifs. *Organic Letters*, **2001**, 3, 1957-60	6.2	36
16	Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. *Journal of Medicinal Chemistry*, **2001**, 44, 2080-93	8.3	105
15	Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei. *Journal of Biological Chemistry*, **2000**, 275, 21870-6	5.4	43
14	Cloning and heterologous expression of the Trypanosoma brucei lanosterol synthase gene. *Molecular and Biochemical Parasitology*, **2000**, 110, 399-403	1.9	24
13	Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine. *Journal of Medicinal Chemistry*, **2000**, 43, 4135-50	8.3	64
12	Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase. *Infection and Immunity*, **1999**, 67, 403-9	3.7	56
11	The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. *Molecular and Biochemical Parasitology*, **1998**, 94, 87-97	1.9	78
10	Protein farnesyltransferase from Trypanosoma brucei. A heterodimer of 61- and 65-kda subunits as a new target for antiparasite therapeutics. *Journal of Biological Chemistry*, **1998**, 273, 26497-505	5.4	50

9	Induction of resistance to azole drugs in Trypanosoma cruzi. *Antimicrobial Agents and Chemotherapy*, **1998**, 42, 3245-50	5.9	61
8	Trypanosoma cruzi: use of herpes simplex virus-thymidine kinase as a negative selectable marker. *Experimental Parasitology*, **1997**, 86, 171-80	2.1	10
7	Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes. *European Journal of Immunology*, **1997**, 27, 2541-8	6.1	13
6	Trypanosoma cruzi: expression of interleukin-2 utilizing both supercoiled plasmids and linear DNAs. *Experimental Parasitology*, **1996**, 83, 159-63	2.1	10
5	Expression of mammalian cytokines by Trypanosoma cruzi indicates unique signal sequence requirements and processing. *Molecular and Biochemical Parasitology*, **1995**, 75, 25-31	1.9	21
4	Hypertension following erythropoietin therapy in anemic hemodialysis patients. *American Journal of Hypertension*, **1990**, 3, 947-55	2.3	80
3	Centrally administered inhibitors of the generation and action of angiotensin II do not attenuate the increase in ACTH secretion produced by ether stress in rats. *Neuroendocrinology*, **1986**, 42, 97-101	5.6	18
2	Immunological Aspects of Cardiac Disease199-230		
1	Spontaneous selection of Cryptosporidium drug resistance in a calf model of infection		1